Kazia Therapeutics received a Buy rating from analyst firm BTIG, which raised its price target to $40, up from $34, reflecting strong confidence in the company's lead drug, paxalisib. The drug showed a 52% tumor reduction in preclinical colorectal cancer models and promising results in breast cancer, prompting an expansion of clinical trials. Kazia also raised $40 million in a recent public offering to support its development efforts. The stock trades around $13, indicating potential growth ahead as the company advances its oncology treatments.
Analyst BTIG upgraded Medtronic to a Buy rating and raised its price target to $100, citing strong Q1 FY2027 revenue of $9.76 billion driven by broad demand. The company is investing over $700 million in Heart Tech and Robotics, signaling a focus on ...
Regis Corporation reported a strong Q4 2026 with earnings per share of $1.04, far exceeding analyst expectations of $0.17. The company generated $56 million in revenue, slightly down year-over-year but above estimates, supported by a 2.6% sales rise ...
UBS analyst Michael Brown reaffirmed a Buy rating on KKR & Co. Inc., setting a $123 price target, implying a 15% upside. KKR is selling USI Insurance Services to Aon plc for $17 billion, expected to yield $3.3 billion in after-tax proceeds and $2 bil...
Cheniere Energy, a leading U.S. liquefied natural gas producer, saw strong institutional confidence with UBS reaffirming its Buy rating. Major investors like Beacon Pointe Advisors and Rakuten Investment Management increased their stakes, signaling o...
Yext reported Q2 earnings with an EPS of $0.21, surpassing analyst estimates of $0.17, resulting in a 23.53% earnings surprise. Despite this, the company's revenue was $111.10 million, slightly below the $111.30 million expected, marking its fourth c...
